Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence

Table 1

Characteristics of 25 included studies in this meta-analysis.

Study	Area	Afatinib	N	Female, n (%)	Age, years, median (range)	Mutations	Clinical stage	ECOG-PS, 0–1/≧2	Histology	Dose reduce, no/yes
Brat, K 2020	Czech	First-line only	147	96 (65.3)	62.8 ± 11.1	EGFR mutation	12 IIIB, 135 IV	147/0	145 AD, 2 other	NR/NR
Chen YH, 2019	Taiwan	First-line only	23	15 (65.2)	42–81	17 Del19, 4 L858R, 2 uncommon	23 advanced	NR	NR	NR/NR
del Re M, 2019	Italy	First-line only	41	20 (48.8)	70.5 ± 11.3	34 Del19, 7 L858R	2 IIIB, 39 IV	NR	NR	26/15
Halmos B, 2019	Global	First-line only	228	138 (60.5)	67.0 (32.0–90.0)	178 Del19, 49 L858R	12 IIIB, 216 IV	192/27 (9 missing)	226 AD, 1 SCC, 1 NOS	51/173
Ho GF, 2019	Malaysia	First-line only	85	47 (55.3)	59.1 ± 10.8	68 Del19, 11 L858R, 6 uncommon	4 IIIB, 81 IV	69/16	82 AD, 3 SCC	49/26
Hsieh YY, 2019	Taiwan	First-line only	751	424 (56.5)	62.5 ± 11.2	EGFR mutation	43 IIIB, 708 IV	678/73	735 AD, 16 other	NR/NR
Igawa S, 2020	Japan	First-line only	48	27 (56)	67 (35–85)	29 Del19, 19 L858R	36 IV, 12 recurrence	24/24	NR	21/27
Ito K, 2020	Japan	Mixed	218	102 (46.8)	64.3 (34–87)	141 Del19, 47 L858R, 30 uncommon	39 IA-IIIA, 11 IIIB, 168 IV	203/12 (3 missing)	208 AD, 10 non-AD	NR/NR
Kan F, 2014	United Kingdom	Second-line or more	63	37 (58.7)	64 (29–83)	15 Del19, 13 L858R, 4 uncommon	63 IV	50/12 (1 missing)	58 AD, 1 SCC, 2 NOS, 1 large cell, 1 unknown	33/31
Kim, Y 2019	Korea	First-line only	165	80 (48.5)	57 (30–79)	114 Del19, 37 L858R, 14 uncommon	165 IV	156/9	NR	53/112
Lau SC, 2019	Canada	First-line only	70	44 (63)	62 (34–84)	41 Del19, 20 L858R, 9 uncommon	70 advanced	68/2	66 AD, 4 other	NR/NR
Li YL, 2019	USA	First-line only	87	62 (71.3)	69 (62–81)	52 Del19, 35 L858R	2 IIIB, 85 IV	31/10 (46 missing)	86 AD, 1 SCC	NR/NR
Liang SK, 2017	Taiwan	First-line only	140	87 (62.1)	61 (28–87)	81 Del19, 24 L858R, 35 uncommon	4 IIIB, 136 IV	129/11	140 AD	81/59
Liang SK, 2018	Taiwan	First-line only	259	157 (60.6)	62 (28–87)	151 Del19, 53 L858R, 55 uncommon	259 advanced	240/19	259 AD	139/120
Lin YT, 2019	Taiwan	First-line only	99	61 (61.6)	60 (53–71) IQR	59 Del19, 23 L858R, 13 uncommon	99 advanced	92/7	95 AD, 4 non-AD	NR/NR
Liu CY, 2017	Taiwan	First-line only	146	78 (53.4)	63.2 ± 11.3	73 Del19, 61 L858R, 12 uncommon	16 IIIB, 130 IV	123/23	146 AD	79/67
Shen YC, 2017	Taiwan	First-line only	24	15 (62.5)	59 (33–86)	24 uncommon	1 IIIB, 23 IV	19/5	24 AD	24/NR
Sonehara K, 2019	Japan	First-line only	62	36 (58.1)	67 (46–85)	42 Del19, 15 L858R, 3 uncommon	5 I-IIIA, 5 IIIB, 40 IV, 13 recurrence	57/5	61 AD, 1 unclassified	23/39
Tamura K, 2019	Japan	Mixed	1602	947 (59.1)	67 (34–90)	1020 Del19, 421 L858R, 137 uncommon	94 IIIB, 1206 IV, other 301, 1 missing	1381/221	1554 AD, 14 SCC, 2 NOS, 1 large cell, 32 others, 1 unknown	580/1008
Tan WL, 2018	Singapore	First-line only	125	61 (48.8)	62 (26–86)	87 Del19, 27 L858R, 11 uncommon	125 IV	NR	121 AD, 1 SCC, 3 NOS	62/62
Tanaka H, 2019	Japan	First-line only	76	52 (68.4)	68 (42–88)	46 Del19, 28 L858R, 2 uncommon	9 IIIB, 45 IV, 22 recurrence	67/9	74 AD, 1 SCC, 1 NOS	18/58
		Second-line or more	52	41 (78.9)	65 (39–90)	29 Del19, 21 L858R, 2 uncommon	52 recurrence	46/6	51 AD, 1 SCC	NR/NR
Tu CY, 2018	Taiwan	First-line only	104	65 (62.5)	58 < 65 years/46 > 65 years	58 Del19, 23 L858R, 23 uncommon	3 IIIB, 101 IV	93/11	104 AD	67/31
Wada Y, 2016	Japan	Mixed	73	46 (63.0)	69 (42–85)	44 Del19, 20 L858R, 5 uncommon, 4 unknown	1 IIIA, 6 IIIB, 44 IV, 22 recurrence	56/17	75 AD	36/37
Wang S, 2019	China	Mixed	60	30 (50.0)	58.1 (36.3–82.7)	26 Del19, 16 L858R, 18 Uncommon	60 advanced	60/0	60 AD	37/23
		First-line only	39	23 (59.0)	57.2 (36.3–82.7)	19 Del19, 7 L858R, 13 uncommon	39 advanced	39/0	39 AD	NR/NR
		Second-line or more	21	7 (33.3)	59.9 (39.7–75.5)	7 Del19, 9 L858R, 5 uncommon	21 advanced	21/0	21 AD	NR/NR
Yang CJ, 2017	Taiwan	First-line only	48	30 (62.5)	64.6 ± 8.9	29 Del19, 19 L858R	48 IV	38/10	48 AD	19/29

NR, not reported; AD, adenocarcinoma; SCC, squamous cell carcinoma; NOS, not otherwise specified; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; IQR, interquartile range.